AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8891846
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg tid)
Trial: 8891846
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg tid)
Trial: 8891846
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet tid)
Trial: 6359724
Drug: Aspirin (50-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50-500 mg)
Trial: 22742765
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of meropenem (2 g loading dose followed by 4 g continuous infusion over 24 hours)
Trial: 22742765
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of meropenem (2 g over 30 minutes every 8 hours)
Trial: 22742765
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of meropenem
Trial: 22742765
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of meropenem
Trial: 17620552
Drug: Initial pramipexole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial pramipexole treatment
Trial: 11903069
Drug: Postoperative 6-hydroxymelatonin
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative 6-hydroxymelatonin sulphate excretion
Trial: 8521893
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (orchiectomy plus placebo)
Trial: 28295934
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (IGlar-U300) 0.4 U/kg once daily
Trial: 26345920
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound (HIFU) therapy under nasal endoscopy guidance
Trial: 26345920
Drug: Corticosteroid nasal
RxNorm normalized name: Corticosteroid nasal preparations for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid nasal spray and oral cetirizine hydrochloride (Control)
Trial: 21311216
Drug: SPEEDA under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPEEDA under Essen 5-dose regimen (group C)
Trial: 17311051
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (70 mg/day for 24 weeks)
Trial: 15321207
Drug: Left lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left lateral position for 10 min after injection
Trial: 15321207
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (S, L, L+R)
Trial: 8840055
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg esmolol
Trial: 8840055
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg esmolol
Trial: 3048753
Drug: Standard commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard commercial preparation of 0.5% bupivacaine
Trial: 26006197
Drug: 2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg PEG powder (17 g in 240 mL water or another beverage) and 5 mg bisacodyl suppository (BD) the day before colonoscopy
Trial: 26006197
Drug: 1.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/kg PEG with fruit juices for two days and 5 mg bisacodyl suppository (BD) for two days before colonoscopy
Trial: 8324855
Drug: Height-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Height-based dosing method
Trial: 8324855
Drug: Physical appearance
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical appearance dosing method
Trial: 25852131
Drug: Electrostimulation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulation plus low molecular weight heparin and below-knee compression stockings (Group 1)
Trial: 25852131
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin and below-knee compression stockings alone (Group 2, control group)
Trial: 18031471
Drug: Nortriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (50 mg daily)
Trial: 11915576
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MPA
Trial: 11915576
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg MPA
Trial: 10736332
Drug: Isoflavone doses
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone doses of 0.8‐1.4 mg/kg
Trial: 10736332
Drug: Isoflavone bioavailability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone bioavailability
Trial: 9344322
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for nonextremity sarcomas
Trial: 1398472
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (rhGH) treatment for 6 months
Trial: 3998766
Drug: Synthetic thymosin-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic thymosin-alpha 1 (loading dose regimen)
Trial: 3998766
Drug: Synthetic thymosin-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic thymosin-alpha 1 (twice‐weekly schedule)
Trial: 30146344
Drug: VR942 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR942 0.5 mg
Trial: 30146344
Drug: VR942 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR942 10 mg
Trial: 30146344
Drug: VR942 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR942 20 mg
Trial: 30146344
Drug: VR942 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR942 (all doses)
Trial: 26834046
Drug: Active encouragement
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active encouragement for diagnostic testing and treatment
Trial: 19962730
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin spray (40 microg) plus diclofenac sodium suppository (100 mg)
Trial: 19962730
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium suppository (100 mg) plus placebo spray (normal saline 0.9%)
Trial: 18375325
Drug: Standard tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tranexamic acid dosing regimen (10 mg/kg over 20 minutes, followed by 1 mg/kg/h)
Trial: 18375325
Drug: New tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New tranexamic acid dosing schedule
Trial: 18375325
Drug: New dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New dosing protocol for tranexamic acid
Trial: 12795227
Drug: Tianbaokang Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianbaokang Injection
Trial: 31054935
Drug: Taurolidine-citrate (T-C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine-citrate (T-C) solution
Trial: 27003917
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg load followed by a continuous infusion of 0.5 μg/kg/h)
Trial: 25216660
Drug: Nonrestorative caries
RxNorm normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonrestorative caries treatment (NRCT; no caries removal, opening up the cavity, teaching brushing and fluoride application)
Trial: 21908204
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) supplementation (600 mg daily for 8 weeks)
Trial: 15729082
Drug: Risperidone (3.6±1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (3.6±1.5 mg/day)
Trial: 3903787
Drug: Ranitidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (0.6 g per day)
Trial: 3903787
Drug: Triletide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triletide (2 g per day)
Trial: 25226857
Drug: Controlled ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian hyperstimulation (COH) - IUI for group 2A (FSH 10-15 mIU/mL and E2<40 pg/mL)
Trial: 25226857
Drug: Controlled ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian hyperstimulation (COH) - IUI for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Trial: 25226857
Drug: IVF for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Trial: 25226857
Drug: Basal FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal FSH of 10-15 mIU/mL and E2≥40 pg/mL
Trial: 23756586
Drug: Walnut-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-enriched diet (56 g of walnuts daily)
Trial: 19834690
Drug: Apomorphine sublingually
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingually (2 mg)
Trial: 19834690
Drug: Apomorphine subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine subcutaneously (0.005 mg/kg)
Trial: 17654304
Drug: INS50589 (0.1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS50589 (0.1-3 mg/kg/h for four hours)
Trial: 13129878
Drug: Routine users
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine users of aspirin
Trial: 13129878
Drug: Routine users
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine users of warfarin
Trial: 13129878
Drug: Discontinued aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinued aspirin use
Trial: 13129878
Drug: Discontinued warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued warfarin use
Trial: 13129878
Drug: Routine continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine continuous users of aspirin
Trial: 13129878
Drug: Routine continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine continuous users of warfarin
Trial: 10383509
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg b.d.
Trial: 2066053
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (500 mg t.i.d.)
Trial: 6316289
Drug: Ketoconazole treatment
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole treatment (daily doses ranged from 3 to 13 mg/Kg, treatment period from 7 days to 14 months)
Trial: 29374667
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine infusion
Trial: 29374667
Drug: No epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No epidural infusion
Trial: 27253224
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) alone or in combination with chemo- and/or radiotherapy
Trial: 16248236
Drug: Maiwei Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maiwei Dihuang Oral Liquid (MDOL) 10 ml twice daily for 3 months
Trial: 16248236
Drug: Prednisone initial
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone initial dose of 0.5-1 mg/kg, reduced conditionally over 6-8 weeks
Trial: 10971320
Drug: Clindamycin 1%/tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1%/tretinoin 0.025% gel (CTG; Velac) applied once daily
Trial: 10971320
Drug: Clindamycin 1%
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% lotion (CLN; Dalacin T) applied twice daily
Trial: 1518664
Drug: Cimetidine (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (7-day administration)
Trial: 1518664
Drug: Famotidine (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (7-day administration)
Trial: 31645451
Drug: etokimab (ANB020),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etokimab (ANB020), an IgG1 anti-IL-33 monoclonal antibody, single systemic administration
Trial: 23839157
Drug: Attenuated RIX4414
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated RIX4414 human rotavirus vaccine
Trial: 18650162
Drug: Observation/no adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation/no adjuvant chemotherapy
Trial: 16569044
Drug: Lyc‐o‐Mato (5.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyc‐o‐Mato (5.7 mg of lycopene, 3.7 mg of phytoene, 2.7 mg of phytofluene, 1 mg of beta‐carotene, and 1.8 mg of alpha‐tocopherol)
Trial: 16569044
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (same taste and flavor, but devoid of active compounds)
Trial: 12518122
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate patch (15 mg)
Trial: 11144400
Drug: Cefdinir 7
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 7 mg/kg twice daily or 14 mg/kg once daily for 10 days or 7 mg/kg twice daily for 5 days
Trial: 11144400
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 10 mg/kg 4 times daily for 10 days
Trial: 9301496
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg twice daily alone (RBC400)
Trial: 9301496
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC400+CLAR)
Trial: 9301496
Drug: RBC 800
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 800 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC800+CLAR)
Trial: 8472526
Drug: Cisapride effervescent
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride effervescent granules (3 sachets daily for 8 weeks)
Trial: 8472526
Drug: Metoclopramide-dimeticone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide-dimeticone combination (3 sachets daily for 8 weeks)
Trial: 8472526
Drug: Metoclopramide-dimeticone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide-dimeticone combination
Trial: 24430917
Drug: Nabiximols (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols (maximum daily dose, 86.4 mg of Δ9‐tetrahydrocannabinol and 80 mg of cannabidiol)
Trial: 16416357
Drug: Lead exposure
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead exposure (mean PbB 5.4 microg Pb/100 ml)
Trial: 16416357
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mean PbB 4.7 microg Pb/100 ml)
Trial: 12391100
Drug: (13)C‐enriched 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (13)C‐enriched 6% CHO(exo) beverage (total volume per trial: 24 ml/kg)
Trial: 10571596
Drug: Oral plus
RxNorm normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral plus topical mesalazine (2.4 g/day oral + 4 g/day topical)
Trial: 10571596
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine (2.4 g/day)
Trial: 8687366
Drug: Exposure in
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure in vivo (group treatment)
Trial: 8687366
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy followed by exposure in vivo (group treatment)
Trial: 8687366
Drug: Cognitive-behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural treatment (integrated from the start, group treatment)
Trial: 8687366
Drug: Individual treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatments
Trial: 2065622
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid (AA) solution
Trial: 29669780
Drug: Torsional phacoemulsification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsional phacoemulsification with adjunctive endocapsular nuclear fragmentation using a manual microinterventional nitinol filament loop device (miLOOP)
Trial: 28728606
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate (1200 mg/day)
Trial: 24860124
Drug: 4% succinylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% succinylated gelatin (Gelofusine, GEL group, n = 40)
Trial: 9423999
Drug: Single 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10 Gy treatment
Trial: 3541803
Drug: D +
RxNorm normalized name: Liver Desiccated + B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D + M (400 mg of doxycycline + 1500 mg of metronidazole)
Trial: 3541803
Drug: D (400
RxNorm normalized name: True Folic Acid (400mcg) 667mcg DFE Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D (400 mg of doxycycline)
Trial: 11388526
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg
Trial: 11388526
Drug: Ropivacaine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 30 mg
Trial: 11388526
Drug: Ropivacaine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 40 mg
Trial: 11388526
Drug: Ropivacaine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 50 mg
Trial: 30643223
Drug: Isocaloric standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric standard treatment for 12 weeks
Trial: 29480843
Drug: Routine primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine primary therapy (Control)
Trial: 24465570
Drug: PHiD-CV (10-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine)
Trial: 22228773
Drug: fenofibrate/pravastatin 160/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate/pravastatin 160/40 mg plus ezetimibe 10 mg (triple therapy)
Trial: 22228773
Drug: simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg plus ezetimibe 10 mg (dual therapy)
Trial: 12107720
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (1 mU/kg per min for 60 min) during adenosine infusion (140 microg/kg per min i.v.)
Trial: 12107720
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (140 microg/kg per min i.v.) without insulin
Trial: 12107720
Drug: Normoglycaemia (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycaemia (plasma glucose 6 mmol/l)
Trial: 10430967
Drug: Hemodialysis patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis patients receiving antihypertensive therapy.
Trial: 8699846
Drug: Pentoxifylline 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 1,200 mg daily for 2 months
Trial: 2347957
Drug: Aspartame (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (15 mg/kg body weight)
Trial: 379366
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy with tetracycline
Trial: 28570250
Drug: NPWTi with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWTi with 0.125% sodium hypochlorite solution
Trial: 26267728
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate gel